pipeline: archive 1 conflict-closed source(s)

Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70>

domains/entertainment/youtube-first-distribution-for-major-studio-coproductions-signals-platform-primacy-over-traditional-broadcast-windowing.md

@@ -53,10 +53,16 @@ Claynosaurz 39-episode animated series launching YouTube-first before selling to
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-05-16-lil-pudgys-youtube-launch-thesoul-reception-data]] | Added: 2026-03-19*
+*Source: 2025-05-16-lil-pudgys-youtube-launch-thesoul-reception-data | Added: 2026-03-19*
 
 Lil Pudgys launched YouTube-first with 13,000 subscribers at premiere (May 2025), relying on TheSoul Publishing's 2B+ social follower network for cross-platform promotion. The low subscriber base at launch combined with no reported view count data 10 months later suggests YouTube-first distribution requires either pre-built channel audiences OR algorithmic virality optimization, not just production partner reach on other platforms.
 
+
+### Additional Evidence (confirm)
+*Source: [[2025-10-01-variety-claynosaurz-creator-led-transmedia]] | Added: 2026-03-19*
+
+Claynosaurz 39-episode animated series launching on YouTube first before selling to TV/streaming, co-produced with Method Animation (Mediawan). Nic Cabana frames this as 'already here' not speculative, with community's 1B social views creating guaranteed algorithmic traction that studios pay millions to achieve through marketing.
+
 ---
 
 Relevant Notes:

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -119,18 +119,6 @@ International generic competition beginning January 2026 (Canada patent expiry,
 
 If GLP-1 + exercise combination produces durable weight maintenance (3.5 kg regain vs 8.7 kg for medication alone), and if behavioral change persists after medication discontinuation, then the chronic use model may not be necessary for long-term value capture. This challenges the inflationary cost projection if the optimal intervention is time-limited medication + permanent behavioral change rather than lifetime pharmacotherapy.
 
-
-### Additional Evidence (challenge)
-*Source: [[2026-02-01-glp1-patent-cliff-generics-global-competition]] | Added: 2026-03-19*
-
-International generic competition beginning in 2026 will compress prices far faster than the 'inflationary through 2035' timeline assumes. Canada's semaglutide patents expired January 4, 2026, with Sandoz, Apotex, and Teva filing immediately. Brazil opens to generics March 2026. China has 17+ Phase 3 generic candidates targeting $40-$50/month pricing. India patents expire March 2026. Even with US patents extending to 2031-2032, international price arbitrage and compounding pharmacy pressure will drive US prices below $100/month by 2030. At $50-100/month, GLP-1s become unambiguously cost-effective under any payment model, fundamentally changing the cost trajectory from inflationary to cost-saving much earlier than 2035.
-
-
-### Additional Evidence (extend)
-*Source: [[2026-02-01-glp1-patent-cliff-generics-global-competition]] | Added: 2026-03-19*
-
-Oral Wegovy launched January 2026 at $149-$299/month with Medicare deal at $245/month, representing 75-85% price compression from injectable formulations. Orforglipron (Eli Lilly non-peptide oral GLP-1) could be approved Q2 2026, adding competitive pressure. The price trajectory is steeper than the chronic-use-inflation model anticipated: oral formulations are already approaching the cost-effectiveness threshold before generics arrive.
-
 ---
 
 Relevant Notes:

entities/ai-alignment/uk-aisi.md

@@ -41,6 +41,14 @@ The first government-established AI safety evaluation body, created after the Bl
 - **2025-07-00** — Conducted international joint testing exercise on agentic systems
 - **2025-05-00** — Released HiBayES statistical modeling framework
 - **2024-04-00** — Released open-source Inspect evaluation framework
+- **2026-03-16** — Conducted cyber capability testing on 7 LLMs on custom-built cyber ranges
+- **2026-03-00** — Renamed from 'AI Safety Institute' to 'AI Security Institute'
+- **2026-02-25** — Released Inspect Scout transcript analysis tool
+- **2026-02-17** — Conducted universal jailbreak assessment against best-defended systems
+- **2025-10-22** — Released ControlArena library for AI control experiments
+- **2025-07-00** — Conducted international joint testing exercise on agentic systems
+- **2025-05-00** — Released HiBayES statistical modeling framework
+- **2024-04-00** — Released open-source Inspect evaluation framework
 ## Alignment Significance
 The UK AISI is the strongest evidence that institutional infrastructure CAN be created from international coordination — but also the strongest evidence that institutional infrastructure without enforcement authority has limited impact. Labs grant access voluntarily. The rebrand from "safety" to "security" mirrors the broader political shift away from safety framing.
 

entities/entertainment/dropout.md

@@ -27,6 +27,7 @@ Creator-owned streaming platform focused on comedy content. Reached 1M+ subscrib
 - **2025-10-01** — Crossed 1 million subscribers (31% YoY growth). Launched $129.99/year superfan tier in response to fan requests for higher-priced support option. Dimension 20 MSG live show sold out (January 2025). Brennan Lee Mulligan signed 3-year deal while simultaneously participating in Critical Role Campaign 4.
 - **2025-10-01** — Crossed 1 million subscribers with 31% YoY growth; launched $129.99/year superfan tier in response to fan requests to support platform
 - **2025-10-01** — Crossed 1 million subscribers (31% YoY growth); launched $129.99/year superfan tier originated by fan request
+- **2025-10-01** — Crossed 1 million subscribers (31% YoY growth). Launched superfan tier at $129.99/year in response to fan requests for higher-priced support option.
 ## Relationship to KB
 
 - [[creator-owned-streaming-infrastructure-has-reached-commercial-scale-with-430M-annual-creator-revenue-across-13M-subscribers]]

inbox/queue/2025-10-01-variety-claynosaurz-creator-led-transmedia.md

@@ -7,9 +7,13 @@ date: 2025-10-01
 domain: entertainment
 secondary_domains: []
 format: article
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [claynosaurz, creator-led, transmedia, youtube-distribution, community-first]
+processed_by: clay
+processed_date: 2026-03-19
+enrichments_applied: ["youtube-first-distribution-for-major-studio-coproductions-signals-platform-primacy-over-traditional-broadcast-windowing.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -45,3 +49,12 @@ Variety article on Nic Cabana's VIEW Conference presentation on Claynosaurz's cr
 PRIMARY CONNECTION: progressive validation through community building reduces development risk by proving audience demand before production investment
 WHY ARCHIVED: Evidences the YouTube-first distribution model as operational (not theoretical) — community as marketing engine for platform-based distribution
 EXTRACTION HINT: The key insight isn't the YouTube distribution per se but the COMMUNITY→ALGORITHM dynamic: pre-existing community creates launch traction that normally costs millions in marketing. This is a specific mechanism claim.
+
+
+## Key Facts
+- Claynosaurz has 39 x 7-minute animated episodes in production
+- Method Animation (Mediawan) is co-production partner
+- Gameloft mobile game in co-development
+- Claynosaurz community has generated nearly 1B social views
+- Nic Cabana presented at VIEW Conference 2025
+- Internal incubator for creative teams planned

inbox/queue/2026-02-01-glp1-patent-cliff-generics-global-competition.md

@@ -7,13 +7,9 @@ date: 2026-02-01
 domain: health
 secondary_domains: [internet-finance]
 format: article
-status: enrichment
+status: unprocessed
 priority: medium
 tags: [glp-1, generics, patent-cliff, global-competition, drug-pricing, market-structure]
-processed_by: vida
-processed_date: 2026-03-19
-enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
-extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -54,15 +50,3 @@ Overview of the GLP-1 generic competition landscape as patents begin expiring in
 PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
 WHY ARCHIVED: Price trajectory is the key variable the existing claim depends on — if prices decline faster than assumed, the "inflationary through 2035" conclusion may be wrong
 EXTRACTION HINT: Focus on the price trajectory and its implications for cost-effectiveness under different payment models, especially the international competition pressure
-
-
-## Key Facts
-- Semaglutide patents extend to 2031-2032 in US and Europe
-- Canada's semaglutide patents expired January 4, 2026
-- Brazil generic competition opens March 2026
-- India semaglutide patents expire March 2026
-- China has 17+ generic semaglutide candidates in Phase 3 trials
-- Oral Wegovy launched January 2026 at $149-$299/month
-- Medicare oral Wegovy deal: $245/month
-- Orforglipron (Lilly) potential approval Q2 2026
-- Amycretin shows 22% weight loss without plateau